SOPHiA GENETICS (NASDAQ:SOPH) Insider Philippe Menu Sells 7,394 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 7,394 shares of SOPHiA GENETICS stock in a transaction on Monday, October 5th. The stock was sold at an average price of $8.13, for a total transaction of $60,113.22. Following the completion of the transaction, the insider directly owned 200,993 shares in the company, valued at $1,634,073.09. This represents a 3.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Philippe Menu also recently made the following trade(s):

• On Tuesday, August 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.68, for a total value of $43,400.00.
• On Wednesday, August 12th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.52, for a total transaction of $37,600.00.
• On Monday, July 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.66, for a total transaction of $28,300.00.
• On Monday, July 13th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total value of $28,500.00.

SOPHiA GENETICS Stock Performance

Shares of SOPHiA GENETICS stock traded down $0.23 on Wednesday, reaching $7.15. 432,750 shares of the stock were exchanged, compared to its average volume of 308,157. The business has a 50 day moving average price of $7.82 and a two-hundred day moving average price of $6.12. The firm has a market capitalization of $599.81 million, a price-to-earnings ratio of -6.22 and a beta of 0.95. SOPHiA GENETICS SA has a twelve month low of $3.75 and a twelve month high of $8.98. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.The company had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. Analysts anticipate that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on SOPH shares. HC Wainwright lifted their price target on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. BTIG Research lifted their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Finally, Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $10.00.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of institutional investors and hedge funds have recently modified their holdings of SOPH. Maven Securities LTD acquired a new position in shares of SOPHiA GENETICS during the 2nd quarter worth about $866,000. AWM Investment Company Inc. purchased a new stake in SOPHiA GENETICS in the 2nd quarter valued at $9,809,000. Sei Investments Co. acquired a new stake in shares of SOPHiA GENETICS during the first quarter worth about $1,772,000. Hennion & Walsh Asset Management Inc. acquired a new stake in SOPHiA GENETICS during the 2nd quarter worth approximately $567,000. Finally, Hodges Capital Management Inc. acquired a new stake in shares of SOPHiA GENETICS during the first quarter worth $2,157,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.